Rentosertib
Insilico Medicine: company profile
Phase 3 registry
Since , the date of the source that reports this phase.
Summary
Rentosertib is a program from Insilico Medicine. The source describes it as small molecule. It is being developed for idiopathic pulmonary fibrosis. ClinicalTrials.gov lists it at Phase 3 (recruiting) under NCT07687459, NCT05938920, NCT05975983, NCT05154240. The AI role named in the source is target and molecule design. Registry records: NCT07687459, Phase 3, recruiting, updated Oct 13, 2026; NCT05938920, Phase 2, completed, updated Dec 11, 2025; NCT05975983, Phase 2, recruiting, updated Nov 12, 2025; NCT05154240, Phase 1, completed, updated Jun 29, 2023. About the company: Pharma.AI, an end-to-end generative AI platform covering target discovery (PandaOmics), molecule generation (Chemistry42) and clinical prediction, backed by lab automation. The latest dated source is from Oct 1, 2026.
Built only from the sources listed on this page.
Facts
- Company
- Insilico Medicine
- Indication
- Idiopathic pulmonary fibrosis
- Therapeutic area
- Respiratory
- Modality
- Small molecule
- AI role
- Target and molecule design
- Phase in the source
- Phase 3 (GENESIS-IPF-3, China), as of Oct 1, 2026
- Phase source
- Registry
- Board column
- Phase 3
AI evidence
AI source: Paper
“rentosertib (formerly ISM001-055), a first-in-class AI-generated small-molecule inhibitor of TNIK”
Source: paper (opens in new tab)
Trial records
- NCT07687459 on ClinicalTrials.gov (opens in new tab) Phase 3 Recruiting Updated
- NCT05938920 on ClinicalTrials.gov (opens in new tab) Phase 2 Completed Updated
- NCT05975983 on ClinicalTrials.gov (opens in new tab) Phase 2 Recruiting Updated
- NCT05154240 on ClinicalTrials.gov (opens in new tab) Phase 1 Completed Updated
Milestone timeline
-
NCT05154240 record updated
Phase 1, Completed
-
NCT05975983 record updated
Phase 2, Recruiting
-
NCT05938920 record updated
Phase 2, Completed
-
Official X post: Phase 3 (GENESIS-IPF-3, China)
-
NCT07687459 record updated
Phase 3, Recruiting
About Insilico Medicine
Pharma.AI, an end-to-end generative AI platform covering target discovery (PandaOmics), molecule generation (Chemistry42) and clinical prediction, backed by lab automation.
Spot an error? Tell me and I'll fix it.